This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, β-Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.

chapter Chapter 1|45 pages

Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes

ByMonika Sharma, Tanya Bajaj, Rohit Sharma

chapter Chapter 2|35 pages


ByMoritz Helmstädter, Manfred Schubert-Zsilavecz

chapter Chapter 4|26 pages

Advancing Phospholipase D Enzymes as Diverse Drug Targets

ByHortênsia Gomes Leala, Kimberly A. Stieglitzb

chapter Chapter 5|27 pages

IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current Perspectives

ByAngelo Paci, Mael Heiblig, Christophe Willekens, Sophie Broutin, Mehdi Touat, Virginie Penard-Lacronique, Stéphane de Bottona

chapter Chapter 6|43 pages

Enzymes for Prodrug-Activation in Cancer Therapy

ByPeter Grunwald

chapter Chapter 7|43 pages

Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer

ByMohammad Hojjat-Farsangi, Gholamreza Khamisipour

chapter Chapter 8|31 pages

β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors

ByUlrike Holzgrabe, Jens Schmitz

chapter Chapter 9|36 pages

Direct Oral Anticoagulants: New Options

BySusanne Alban

chapter Chapter 10|35 pages

Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease

ByBrian Yu, Nikola Sladojevic, James K. Liao

chapter Chapter 11|92 pages

Lysosomal Storage Disorders and Enzyme Replacement Therapy

ByPeter Grunwald